{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:11:25Z","timestamp":1791558685993,"version":"4.3.4"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10555-024-10220-8","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:27:42Z","timestamp":1732523262000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-4767","authenticated-orcid":false,"given":"Linjie","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5780-9885","authenticated-orcid":false,"given":"Yiwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-0487","authenticated-orcid":false,"given":"Yunjie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"10220_CR1","doi-asserted-by":"publisher","unstructured":"Raso, M. G., Bota-Rabassedas, N., & Wistuba, I. I. (2021). Pathology and classification of SCLC. Cancers (Basel), 13(4). https:\/\/doi.org\/10.3390\/cancers13040820","DOI":"10.3390\/cancers13040820"},{"issue":"3","key":"10220_CR2","doi-asserted-by":"publisher","first-page":"e224830","DOI":"10.1001\/jamanetworkopen.2022.4830","volume":"5","author":"JS Tseng","year":"2022","unstructured":"Tseng, J. S., Chiang, C. J., Chen, K. C., Zheng, Z. R., Yang, T. Y., Lee, W. C., et al. (2022). Association of smoking with patient characteristics and outcomes in small cell lung carcinoma, 2011\u20132018. JAMA Network Open, 5(3), e224830. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.4830","journal-title":"JAMA Network Open"},{"issue":"4","key":"10220_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.21037\/tlcr.2016.07.02","volume":"5","author":"N Karachaliou","year":"2016","unstructured":"Karachaliou, N., Sosa, A. E., & Rosell, R. (2016). Unraveling the genomic complexity of small cell lung cancer. Transl Lung Cancer Res, 5(4), 363\u2013366. https:\/\/doi.org\/10.21037\/tlcr.2016.07.02","journal-title":"Translational Lung Cancer Research"},{"issue":"3","key":"10220_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccell.2021.02.002","volume":"39","author":"KK Frese","year":"2021","unstructured":"Frese, K. K., Simpson, K. L., & Dive, C. (2021). Small cell lung cancer enters the era of precision medicine. Cancer Cell, 39(3), 297\u2013299. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.002","journal-title":"Cancer Cell"},{"issue":"12","key":"10220_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017). Small-cell lung cancer: What we know, what we need to know and the path forward. Nature Reviews Cancer, 17(12), 725\u2013737. https:\/\/doi.org\/10.1038\/nrc.2017.87","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10220_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021). Small-cell lung cancer. Nat Rev Dis Primers, 7(1), 3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10220_CR7","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3322\/caac.21785","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., et al. (2023). Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. C Ca: A Cancer Journal for Clinicians, 73(6), 620\u2013652. https:\/\/doi.org\/10.3322\/caac.21785","journal-title":"C Ca: A Cancer Journal for Clinicians"},{"issue":"1","key":"10220_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki, M., Hemminki, A., Fallah, M., Thomsen, H., Sundquist, K., Sundquist, J., et al. (2014). Metastatic sites and survival in lung cancer. Lung Cancer, 86(1), 78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020","journal-title":"Lung Cancer"},{"issue":"1","key":"10220_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","volume":"7","author":"DI Tsilimigras","year":"2021","unstructured":"Tsilimigras, D. I., Brodt, P., Clavien, P. A., Muschel, R. J., D\u2019Angelica, M. I., Endo, I., et al. (2021). Liver metastases. Nat Rev Dis Primers, 7(1), 27. https:\/\/doi.org\/10.1038\/s41572-021-00261-6","journal-title":"Nature Reviews Disease Primers"},{"issue":"33","key":"10220_CR10","doi-asserted-by":"publisher","first-page":"53245","DOI":"10.18632\/oncotarget.10644","volume":"7","author":"Y Ren","year":"2016","unstructured":"Ren, Y., Dai, C., Zheng, H., Zhou, F., She, Y., Jiang, G., et al. (2016). Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget, 7(33), 53245\u201353253. https:\/\/doi.org\/10.18632\/oncotarget.10644","journal-title":"Oncotarget"},{"issue":"1","key":"10220_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/1878-0261.12022","volume":"11","author":"A Dasgupta","year":"2017","unstructured":"Dasgupta, A., Lim, A. R., & Ghajar, C. M. (2017). Circulating and disseminated tumor cells: Harbingers or initiators of metastasis? Molecular Oncology, 11(1), 40\u201361. https:\/\/doi.org\/10.1002\/1878-0261.12022","journal-title":"Molecular Oncology"},{"key":"10220_CR12","doi-asserted-by":"publisher","unstructured":"Gibert-Ramos, A., Sanfeliu-Redondo, D., Aristu-Zabalza, P., Mart\u00ednez-Alcocer, A., Gracia-Sancho, J., Guix\u00e9-Muntet, S., et al. (2021). The hepatic sinusoid in Chronic Liver Disease: The optimal milieu for Cancer. Cancers (Basel), 13(22). https:\/\/doi.org\/10.3390\/cancers13225719","DOI":"10.3390\/cancers13225719"},{"issue":"11","key":"10220_CR13","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.7150\/jca.23989","volume":"9","author":"X Liu","year":"2018","unstructured":"Liu, X., Li, C., Li, J., Yu, T., Zhou, G., Cheng, J., et al. (2018). Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. Journal of Cancer, 9(11), 2038\u20132045. https:\/\/doi.org\/10.7150\/jca.23989","journal-title":"Journal of Cancer"},{"issue":"9","key":"10220_CR14","doi-asserted-by":"publisher","first-page":"e12125","DOI":"10.1002\/jev2.12125","volume":"10","author":"F Urabe","year":"2021","unstructured":"Urabe, F., Patil, K., Ramm, G. A., Ochiya, T., & Soekmadji, C. (2021). Extracellular vesicles in the development of organ-specific metastasis. Journal of Extracellular Vesicles, 10(9), e12125. https:\/\/doi.org\/10.1002\/jev2.12125","journal-title":"Journal of Extracellular Vesicles"},{"issue":"9","key":"10220_CR15","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1373\/clinchem.2013.202846","volume":"59","author":"E Den\u00e8ve","year":"2013","unstructured":"Den\u00e8ve, E., Riethdorf, S., Ramos, J., Nocca, D., Coffy, A., Daur\u00e8s, J. P., et al. (2013). Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clinical Chemistry, 59(9), 1384\u20131392. https:\/\/doi.org\/10.1373\/clinchem.2013.202846","journal-title":"Clinical Chemistry"},{"issue":"Pt 2","key":"10220_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","volume":"86","author":"T Li","year":"2022","unstructured":"Li, T., & Qiao, T. (2022). Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy. Seminars in Cancer Biology, 86(Pt 2), 117\u2013125. https:\/\/doi.org\/10.1016\/j.semcancer.2022.09.005","journal-title":"Seminars in Cancer Biology"},{"key":"10220_CR17","doi-asserted-by":"publisher","first-page":"175883592093303","DOI":"10.1177\/1758835920933034","volume":"12","author":"T Jin","year":"2020","unstructured":"Jin, T., Dai, C., & Xu, F. (2020). Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: Recent advances and future prospects. Therapeutic Advances in Medical Oncology, 12, 1758835920933034. https:\/\/doi.org\/10.1177\/1758835920933034","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"4","key":"10220_CR18","first-page":"1648","volume":"12","author":"W Li","year":"2022","unstructured":"Li, W., Zhou, J., Zhang, T., Tai, Y., Xu, Y., Bai, Y., et al. (2022). A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases. American Journal of Cancer Research, 12(4), 1648\u20131659.","journal-title":"American Journal of Cancer Research"},{"issue":"1","key":"10220_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13063-018-2499-5","volume":"19","author":"K Gurusamy","year":"2018","unstructured":"Gurusamy, K., Corrigan, N., Croft, J., Twiddy, M., Morris, S., Woodward, N., et al. (2018). Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases (LAVA): Study protocol for a randomised controlled trial. Trials, 19(1), 105. https:\/\/doi.org\/10.1186\/s13063-018-2499-5","journal-title":"Trials"},{"issue":"2","key":"10220_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1148\/radiol.12112544","volume":"266","author":"AH Mahnken","year":"2013","unstructured":"Mahnken, A. H., Pereira, P. L., & de Ba\u00e8re, T. (2013). Interventional oncologic approaches to liver metastases. Radiology, 266(2), 407\u2013430. https:\/\/doi.org\/10.1148\/radiol.12112544","journal-title":"Radiology"},{"issue":"4","key":"10220_CR21","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1007\/s00330-020-07253-2","volume":"31","author":"TJ Vogl","year":"2021","unstructured":"Vogl, T. J., Marko, C., Langenbach, M. C., Naguib, N. N. N., Filmann, N., Hammerstingl, R., et al. (2021). Transarterial chemoembolization of colorectal cancer liver metastasis: Improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. European Radiology, 31(4), 2242\u20132251. https:\/\/doi.org\/10.1007\/s00330-020-07253-2","journal-title":"European Radiology"},{"issue":"1","key":"10220_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","volume":"7","author":"AF Farago","year":"2018","unstructured":"Farago, A. F., & Keane, F. K. (2018). Current standards for clinical management of small cell lung cancer. Translational Lung Cancer Research, 7(1), 69\u201379. https:\/\/doi.org\/10.21037\/tlcr.2018.01.16","journal-title":"Translational Lung Cancer Research"},{"issue":"6","key":"10220_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/jco.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia, J., & Paz-Ares, L. (2022). Extensive-stage small-cell Lung Cancer: First-line and second-line treatment options. Journal of Clinical Oncology, 40(6), 671\u2013680. https:\/\/doi.org\/10.1200\/jco.21.01881","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10220_CR24","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., et al. (2022). Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell Lung Cancer: The ASTRUM-005 randomized clinical trial. JAMA, 328(12), 1223\u20131232. https:\/\/doi.org\/10.1001\/jama.2022.16464","journal-title":"JAMA"},{"issue":"6","key":"10220_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., et al. (2022). Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 23(6), 739\u2013747. https:\/\/doi.org\/10.1016\/s1470-2045(22)00224-8","journal-title":"The Lancet Oncology"},{"issue":"18","key":"10220_CR26","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.18632\/aging.205035","volume":"15","author":"Y Lin","year":"2023","unstructured":"Lin, Y., Jiang, W., Su, C. Y., & Pan, X. B. (2023). Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: A systematic review and meta-analysis. Aging (Albany NY), 15(18), 9561\u20139571. https:\/\/doi.org\/10.18632\/aging.205035","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10220_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.21037\/hbsn-21-215","volume":"10","author":"N Cortese","year":"2021","unstructured":"Cortese, N., & Marchesi, F. (2021). Liver metastases siphon off immunotherapy response. Hepatobiliary Surgery and Nutrition, 10(4), 526\u2013529. https:\/\/doi.org\/10.21037\/hbsn-21-215","journal-title":"Hepatobiliary Surgery and Nutrition"},{"issue":"1","key":"10220_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.Ccr-21-1193","volume":"28","author":"JC Lee","year":"2022","unstructured":"Lee, J. C., Green, M. D., Huppert, L. A., Chow, C., Pierce, R. H., & Daud, A. I. (2022). The liver-immunity Nexus and Cancer Immunotherapy. Clinical Cancer Research, 28(1), 5\u201312. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1193","journal-title":"Clinical Cancer Research"},{"key":"10220_CR29","doi-asserted-by":"publisher","unstructured":"Liver Metastases Impede Checkpoint Inhibitors (2021). Cancer Discover, 11(3), Of2, https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2021-0304","DOI":"10.1158\/2159-8290.Cd-nb2021-0304"},{"issue":"1","key":"10220_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., et al. (2021). Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 27(1), 152\u2013164. https:\/\/doi.org\/10.1038\/s41591-020-1131-x","journal-title":"Nature Medicine"},{"issue":"4","key":"10220_CR31","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/2159-8290.Cd-21-0010","volume":"11","author":"J Massagu\u00e9","year":"2021","unstructured":"Massagu\u00e9, J., & Ganesh, K. (2021). Metastasis-initiating cells and ecosystems. Cancer Discovery, 11(4), 971\u2013994. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0010","journal-title":"Cancer Discovery"},{"issue":"3","key":"10220_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.celrep.2016.06.021","volume":"16","author":"NS Jahchan","year":"2016","unstructured":"Jahchan, N. S., Lim, J. S., Bola, B., Morris, K., Seitz, G., Tran, K. Q., et al. (2016). Identification and targeting of long-term tumor-propagating cells in small cell Lung Cancer. Cell Rep, 16(3), 644\u2013656. https:\/\/doi.org\/10.1016\/j.celrep.2016.06.021","journal-title":"Cell Rep"},{"issue":"1","key":"10220_CR33","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1038\/s41467-018-07077-1","volume":"9","author":"SP Rowbotham","year":"2018","unstructured":"Rowbotham, S. P., Li, F., Dost, A. F. M., Louie, S. M., Marsh, B. P., Pessina, P., et al. (2018). H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nature Communications, 9(1), 4559. https:\/\/doi.org\/10.1038\/s41467-018-07077-1","journal-title":"Nature Communications"},{"issue":"1","key":"10220_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3978\/j.issn.2218-6751.2016.01.01","volume":"5","author":"J Codony-Servat","year":"2016","unstructured":"Codony-Servat, J., Verlicchi, A., & Rosell, R. (2016). Cancer stem cells in small cell lung cancer. Translational Lung Cancer Research, 5(1), 16\u201325. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2016.01.01","journal-title":"Translational Lung Cancer Research"},{"key":"10220_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.semcancer.2022.11.006","volume":"87","author":"W Guo","year":"2022","unstructured":"Guo, W., Qiao, T., & Li, T. (2022). The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy. Seminars in Cancer Biology, 87, 160\u2013169. https:\/\/doi.org\/10.1016\/j.semcancer.2022.11.006","journal-title":"Seminars in Cancer Biology"},{"issue":"1","key":"10220_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-017-0596-9","volume":"16","author":"TB Toh","year":"2017","unstructured":"Toh, T. B., Lim, J. J., & Chow, E. K. (2017). Epigenetics in cancer stem cells. Molecular Cancer, 16(1), 29. https:\/\/doi.org\/10.1186\/s12943-017-0596-9","journal-title":"Molecular Cancer"},{"issue":"8","key":"10220_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1101\/gad.277681.116","volume":"30","author":"T Celia-Terrassa","year":"2016","unstructured":"Celia-Terrassa, T., & Kang, Y. (2016). Distinctive properties of metastasis-initiating cells. Genes & Development, 30(8), 892\u2013908. https:\/\/doi.org\/10.1101\/gad.277681.116","journal-title":"Genes & Development"},{"key":"10220_CR38","doi-asserted-by":"publisher","unstructured":"Celia-Terrassa, T., & Jolly, M. K. (2020). Cancer stem cells and epithelial-to-mesenchymal transition in cancer metastasis. Cold Spring Harbor Perspectives in Medicine, 10(7). https:\/\/doi.org\/10.1101\/cshperspect.a036905","DOI":"10.1101\/cshperspect.a036905"},{"issue":"1","key":"10220_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang, Y., Hong, W., & Wei, X. (2022). The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology & Oncology, 15(1), 129. https:\/\/doi.org\/10.1186\/s13045-022-01347-8","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10220_CR40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41421-024-00687-8","volume":"10","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Guo, C., Cai, X., Hu, L., Tong, X., Xue, Y., et al. (2024). Genetic tracing uncovers the importance of epithelial-to-mesenchymal transition in small cell lung cancer chemotherapy resistance but not metastasis. Cell Discovery, 10(1), 60. https:\/\/doi.org\/10.1038\/s41421-024-00687-8","journal-title":"Cell Discovery"},{"issue":"10","key":"10220_CR41","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ng.2396","volume":"44","author":"M Peifer","year":"2012","unstructured":"Peifer, M., Fern\u00e1ndez-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., et al. (2012). Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 44(10), 1104\u20131110. https:\/\/doi.org\/10.1038\/ng.2396","journal-title":"Nature Genetics"},{"key":"10220_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bcp.2018.12.010","volume":"160","author":"WS Heng","year":"2019","unstructured":"Heng, W. S., Gosens, R., & Kruyt, F. A. E. (2019). Lung cancer stem cells: Origin, features, maintenance mechanisms and therapeutic targeting. Biochemical Pharmacology, 160, 121\u2013133. https:\/\/doi.org\/10.1016\/j.bcp.2018.12.010","journal-title":"Biochemical Pharmacology"},{"issue":"11","key":"10220_CR43","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan, J. M., Quintanal-Villalonga, A., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., et al. (2021). Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 39(11), 1479\u20131496. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.008","journal-title":"Cancer Cell"},{"issue":"12","key":"10220_CR44","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016). The epidemiology of metastases in neuroendocrine tumors. International Journal of Cancer, 139(12), 2679\u20132686. https:\/\/doi.org\/10.1002\/ijc.30400","journal-title":"International Journal of Cancer"},{"issue":"8","key":"10220_CR45","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/bjc.2013.112","volume":"108","author":"R Stovold","year":"2013","unstructured":"Stovold, R., Meredith, S. L., Bryant, J. L., Babur, M., Williams, K. J., Dean, E. J., et al. (2013). Neuroendocrine and epithelial phenotypes in small-cell lung cancer: Implications for metastasis and survival in patients. British Journal of Cancer, 108(8), 1704\u20131711. https:\/\/doi.org\/10.1038\/bjc.2013.112","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10220_CR46","doi-asserted-by":"publisher","first-page":"101610","DOI":"10.1016\/j.xcrm.2024.101610","volume":"5","author":"P Desai","year":"2024","unstructured":"Desai, P., Takahashi, N., Kumar, R., Nichols, S., Malin, J., Hunt, A., et al. (2024). Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities. Cell Reports Medicine, 5(6), 101610. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101610","journal-title":"Cell Reports Medicine"},{"issue":"15","key":"10220_CR47","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1101\/gad.262998.115","volume":"29","author":"MC Kwon","year":"2015","unstructured":"Kwon, M. C., Proost, N., Song, J. Y., Sutherland, K. D., Zevenhoven, J., & Berns, A. (2015). Paracrine signaling between tumor subclones of mouse SCLC: A critical role of ETS transcription factor Pea3 in facilitating metastasis. Genes & Development, 29(15), 1587\u20131592. https:\/\/doi.org\/10.1101\/gad.262998.115","journal-title":"Genes & Development"},{"issue":"7547","key":"10220_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature14403","volume":"520","author":"E Wagenblast","year":"2015","unstructured":"Wagenblast, E., Soto, M., Guti\u00e9rrez-\u00c1ngel, S., Hartl, C. A., Gable, A. L., Maceli, A. R., et al. (2015). A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature, 520(7547), 358\u2013362. https:\/\/doi.org\/10.1038\/nature14403","journal-title":"Nature"},{"issue":"10","key":"10220_CR49","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jtho.2023.07.012","volume":"18","author":"SM Pearsall","year":"2023","unstructured":"Pearsall, S. M., Williamson, S. C., Humphrey, S., Hughes, E., Morgan, D., Garc\u00eda Marqu\u00e9s, F. J., et al. (2023). Lineage plasticity in SCLC generates non-neuroendocrine cells primed for Vasculogenic Mimicry. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 18(10), 1362\u20131385. https:\/\/doi.org\/10.1016\/j.jtho.2023.07.012","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"7654","key":"10220_CR50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim, J. S., Ibaseta, A., Fischer, M. M., Cancilla, B., O\u2019Young, G., Cristea, S., et al. (2017). Intratumoural heterogeneity generated by notch signalling promotes small-cell lung cancer. Nature, 545(7654), 360\u2013364. https:\/\/doi.org\/10.1038\/nature22323","journal-title":"Nature"},{"issue":"1","key":"10220_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland, A. S., Micinski, A. M., Kastner, D. W., Guo, B., Wait, S. J., Spainhower, K. B., et al. (2020). MYC drives temporal evolution of small cell Lung Cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell, 38(1), 60\u201378e12. https:\/\/doi.org\/10.1016\/j.ccell.2020.05.001","journal-title":"Cancer Cell"},{"issue":"1","key":"10220_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.21037\/tlcr.2018.01.15","volume":"7","author":"YT Shue","year":"2018","unstructured":"Shue, Y. T., Lim, J. S., & Sage, J. (2018). Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. Transl Lung Cancer Res, 7(1), 21\u201331. https:\/\/doi.org\/10.21037\/tlcr.2018.01.15","journal-title":"Translational Lung Cancer Research"},{"issue":"2","key":"10220_CR53","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccr.2010.12.021","volume":"19","author":"J Calbo","year":"2011","unstructured":"Calbo, J., van Montfort, E., Proost, N., van Drunen, E., Beverloo, H. B., Meuwissen, R., et al. (2011). A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell, 19(2), 244\u2013256. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.021","journal-title":"Cancer Cell"},{"issue":"3","key":"10220_CR54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.celrep.2016.06.020","volume":"16","author":"EA Semenova","year":"2016","unstructured":"Semenova, E. A., Kwon, M. C., Monkhorst, K., Song, J. Y., Bhaskaran, R., Krijgsman, O., et al. (2016). Transcription factor NFIB is a driver of small cell Lung Cancer Progression in mice and marks metastatic disease in patients. Cell Reports, 16(3), 631\u2013643. https:\/\/doi.org\/10.1016\/j.celrep.2016.06.020","journal-title":"Cell Reports"},{"key":"10220_CR55","doi-asserted-by":"publisher","unstructured":"Yang, D., Qu, F., Cai, H., Chuang, C. H., Lim, J. S., Jahchan, N., et al. (2019). Axon-like protrusions promote small cell lung cancer migration and metastasis. Elife, 8. https:\/\/doi.org\/10.7554\/eLife.50616","DOI":"10.7554\/eLife.50616"},{"issue":"2","key":"10220_CR56","first-page":"457","volume":"60","author":"N Guo","year":"2000","unstructured":"Guo, N., Templeton, N. S., Al-Barazi, H., Cashel, J. A., Sipes, J. M., Krutzsch, H. C., et al. (2000). Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Research, 60(2), 457\u2013466.","journal-title":"Cancer Research"},{"issue":"2","key":"10220_CR57","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.cell.2016.05.052","volume":"166","author":"SK Denny","year":"2016","unstructured":"Denny, S. K., Yang, D., Chuang, C. H., Brady, J. J., Lim, J. S., Gruner, B. M., et al. (2016). Nfib Promotes Metastasis through a widespread increase in chromatin accessibility. Cell, 166(2), 328\u2013342. https:\/\/doi.org\/10.1016\/j.cell.2016.05.052","journal-title":"Cell"},{"issue":"1","key":"10220_CR58","doi-asserted-by":"publisher","first-page":"e13122","DOI":"10.15252\/emmm.202013122","volume":"13","author":"J Ko","year":"2021","unstructured":"Ko, J., Winslow, M. M., & Sage, J. (2021). Mechanisms of small cell lung cancer metastasis. Embo Molecular Medicine, 13(1), e13122. https:\/\/doi.org\/10.15252\/emmm.202013122","journal-title":"Embo Molecular Medicine"},{"issue":"14","key":"10220_CR59","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1101\/gad.2046711","volume":"25","author":"AL Dooley","year":"2011","unstructured":"Dooley, A. L., Winslow, M. M., Chiang, D. Y., Banerji, S., Stransky, N., Dayton, T. L., et al. (2011). Nuclear factor I\/B is an oncogene in small cell lung cancer. Genes & Development, 25(14), 1470\u20131475. https:\/\/doi.org\/10.1101\/gad.2046711","journal-title":"Genes & Development"},{"issue":"2","key":"10220_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu, G., Guthrie, M. R., Bohm, S., Bragelmann, J., Can, I., Ballieu, P. M., et al. (2017). MYC drives progression of small cell Lung Cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition. Cancer Cell, 31(2), 270\u2013285. https:\/\/doi.org\/10.1016\/j.ccell.2016.12.005","journal-title":"Cancer Cell"},{"issue":"5","key":"10220_CR61","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., et al. (2019). Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data. Nature Reviews Cancer, 19(5), 289\u2013297. https:\/\/doi.org\/10.1038\/s41568-019-0133-9","journal-title":"Nature Reviews Cancer"},{"issue":"15_suppl","key":"10220_CR62","doi-asserted-by":"publisher","first-page":"8508","DOI":"10.1200\/JCO.2021.39.15_suppl.8508","volume":"39","author":"S Puri","year":"2021","unstructured":"Puri, S., Naqash, A. R., Elliott, A., Kerrigan, K. C., Patel, S. B., Seeber, A., et al. (2021). Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers. Journal of Clinical Oncology, 39(15_suppl), 8508\u20138508. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8508","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10220_CR63","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., et al. (2021). Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 39(3), 346\u2013360e347. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014","journal-title":"Cancer Cell"},{"issue":"12","key":"10220_CR64","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine, M. K., Hsieh, M. S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., et al. (2020). SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 15(12), 1823\u20131835. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.009","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"13\u201314","key":"10220_CR65","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"YH Huang","year":"2018","unstructured":"Huang, Y. H., Klingbeil, O., He, X. Y., Wu, X. S., Arun, G., Lu, B., et al. (2018). POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes & Development, 32(13\u201314), 915\u2013928. https:\/\/doi.org\/10.1101\/gad.314815.118","journal-title":"Genes & Development"},{"issue":"1","key":"10220_CR66","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/s41467-023-41585-z","volume":"14","author":"Z Wu","year":"2023","unstructured":"Wu, Z., Su, J., Li, F. L., Chen, T., Mayner, J., Engler, A., et al. (2023). YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis. Nature Communications, 14(1), 5916. https:\/\/doi.org\/10.1038\/s41467-023-41585-z","journal-title":"Nature Communications"},{"key":"10220_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.11.005","volume":"87","author":"P Khan","year":"2022","unstructured":"Khan, P., Fatima, M., Khan, M. A., Batra, S. K., & Nasser, M. W. (2022). Emerging role of chemokines in small cell lung cancer: Road signs for metastasis, heterogeneity, and immune response. Seminars in Cancer Biology, 87, 117\u2013126. https:\/\/doi.org\/10.1016\/j.semcancer.2022.11.005","journal-title":"Seminars in Cancer Biology"},{"key":"10220_CR68","doi-asserted-by":"publisher","unstructured":"Araujo, A. M., Abaurrea, A., Azcoaga, P., Lopez-Velazco, J. I., Manzano, S., Rodriguez, J., et al. (2022). Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. Journal of Clinical Investigation, 132(19). https:\/\/doi.org\/10.1172\/JCI165107","DOI":"10.1172\/JCI165107"},{"issue":"1","key":"10220_CR69","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s41467-022-28933-1","volume":"13","author":"EA Kwak","year":"2022","unstructured":"Kwak, E. A., Pan, C. C., Ramonett, A., Kumar, S., Cruz-Flores, P., Ahmed, T., et al. (2022). beta(IV)-spectrin as a stalk cell-intrinsic regulator of VEGF signaling. Nature Communications, 13(1), 1326. https:\/\/doi.org\/10.1038\/s41467-022-28933-1","journal-title":"Nature Communications"},{"issue":"20","key":"10220_CR70","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1016\/j.febslet.2012.08.011","volume":"586","author":"Y Otani","year":"2012","unstructured":"Otani, Y., Kijima, T., Kohmo, S., Oishi, S., Minami, T., Nagatomo, I., et al. (2012). Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016. FEBS Letters, 586(20), 3639\u20133644. https:\/\/doi.org\/10.1016\/j.febslet.2012.08.011","journal-title":"FEBS Letters"},{"issue":"27","key":"10220_CR71","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1038\/sj.onc.1208621","volume":"24","author":"TN Hartmann","year":"2005","unstructured":"Hartmann, T. N., Burger, J. A., Glodek, A., Fujii, N., & Burger, M. (2005). CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 24(27), 4462\u20134471. https:\/\/doi.org\/10.1038\/sj.onc.1208621","journal-title":"Oncogene"},{"issue":"3","key":"10220_CR72","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/01.coc.0000054894.64867.80","volume":"27","author":"F Oshita","year":"2004","unstructured":"Oshita, F., Kameda, Y., Hamanaka, N., Saito, H., Yamada, K., Noda, K., et al. (2004). High expression of integrin beta1 and p53 is a greater poor prognostic factor than clinical stage in small-cell lung cancer. American Journal of Clinical Oncology, 27(3), 215\u2013219. https:\/\/doi.org\/10.1097\/01.coc.0000054894.64867.80","journal-title":"American Journal of Clinical Oncology"},{"issue":"3","key":"10220_CR73","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1172\/JCI122779","volume":"129","author":"G Zhao","year":"2019","unstructured":"Zhao, G., Gong, L., Su, D., Jin, Y., Guo, C., Yue, M., et al. (2019). Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin beta1. J Clin Invest, 129(3), 972\u2013987. https:\/\/doi.org\/10.1172\/JCI122779","journal-title":"Journal of Clinical Investigation"},{"issue":"11","key":"10220_CR74","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/sj.bjc.6602227","volume":"91","author":"YM Zhu","year":"2004","unstructured":"Zhu, Y. M., Webster, S. J., Flower, D., & Woll, P. J. (2004). Interleukin-8\/CXCL8 is a growth factor for human lung cancer cells. British Journal of Cancer, 91(11), 1970\u20131976. https:\/\/doi.org\/10.1038\/sj.bjc.6602227","journal-title":"British Journal of Cancer"},{"key":"10220_CR75","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lungcan.2021.11.003","volume":"162","author":"Q Liu","year":"2021","unstructured":"Liu, Q., Qiao, M., Lohinai, Z., Mao, S., Pan, Y., Wang, Y., et al. (2021). CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer. Lung Cancer, 162, 194\u2013202. https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.003","journal-title":"Lung Cancer"},{"key":"10220_CR76","doi-asserted-by":"publisher","unstructured":"Korbecki, J., Kojder, K., Barczak, K., Simi\u0144ska, D., Gutowska, I., Chlubek, D., et al. (2020). Hypoxia alters the expression of CC chemokines and CC Chemokine Receptors in a Tumor-A Literature Review. International Journal of Molecular Sciences, 21(16). https:\/\/doi.org\/10.3390\/ijms21165647","DOI":"10.3390\/ijms21165647"},{"issue":"12","key":"10220_CR77","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrc2540","volume":"8","author":"JA Bertout","year":"2008","unstructured":"Bertout, J. A., Patel, S. A., & Simon, M. C. (2008). The impact of O2 availability on human cancer. Nature Reviews Cancer, 8(12), 967\u2013975. https:\/\/doi.org\/10.1038\/nrc2540","journal-title":"Nature Reviews Cancer"},{"issue":"Pt 3","key":"10220_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang, Y., & Cao, Y. (2022). The impact of VEGF on cancer metastasis and systemic disease. Seminars in Cancer Biology, 86(Pt 3), 251\u2013261. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.011","journal-title":"Seminars in Cancer Biology"},{"key":"10220_CR79","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.1038\/ncomms13322","volume":"7","author":"SC Williamson","year":"2016","unstructured":"Williamson, S. C., Metcalf, R. L., Trapani, F., Mohan, S., Antonello, J., Abbott, B., et al. (2016). Vasculogenic mimicry in small cell lung cancer. Nature Communications, 7, 13322. https:\/\/doi.org\/10.1038\/ncomms13322","journal-title":"Nature Communications"},{"key":"10220_CR80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.canlet.2020.11.029","volume":"499","author":"G Spanier","year":"2021","unstructured":"Spanier, G., Ugele, I., Nieberle, F., Symeou, L., Schmidhofer, S., Brand, A., et al. (2021). The predictive power of CD3(+) T cell infiltration of oral squamous cell tumors is limited to non-diabetic patients. Cancer Letters, 499, 209\u2013219. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.029","journal-title":"Cancer Letters"},{"issue":"8","key":"10220_CR81","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jcb.25488","volume":"117","author":"H Smith","year":"2016","unstructured":"Smith, H., Board, M., Pellagatti, A., Turley, H., Boultwood, J., & Callaghan, R. (2016). The effects of severe hypoxia on glycolytic flux and enzyme activity in a model of solid tumors. Journal of Cellular Biochemistry, 117(8), 1890\u20131901. https:\/\/doi.org\/10.1002\/jcb.25488","journal-title":"Journal of Cellular Biochemistry"},{"key":"10220_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.semcancer.2021.10.002","volume":"85","author":"M Ivan","year":"2022","unstructured":"Ivan, M., Fishel, M. L., Tudoran, O. M., Pollok, K. E., Wu, X., & Smith, P. J. (2022). Hypoxia signaling: Challenges and opportunities for cancer therapy. Seminars in Cancer Biology, 85, 185\u2013195. https:\/\/doi.org\/10.1016\/j.semcancer.2021.10.002","journal-title":"Seminars in Cancer Biology"},{"issue":"Pt 2","key":"10220_CR83","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semcancer.2022.07.003","volume":"86","author":"G Bononi","year":"2022","unstructured":"Bononi, G., Masoni, S., Di Bussolo, V., Tuccinardi, T., Granchi, C., & Minutolo, F. (2022). Historical perspective of tumor glycolysis: A century with Otto Warburg. Seminars in Cancer Biology, 86(Pt 2), 325\u2013333. https:\/\/doi.org\/10.1016\/j.semcancer.2022.07.003","journal-title":"Seminars in Cancer Biology"},{"key":"10220_CR84","doi-asserted-by":"publisher","unstructured":"Schiliro, C., & Firestein, B. L. (2021). Mechanisms of metabolic reprogramming in Cancer cells supporting enhanced growth and proliferation. Cells, 10(5). https:\/\/doi.org\/10.3390\/cells10051056","DOI":"10.3390\/cells10051056"},{"key":"10220_CR85","doi-asserted-by":"publisher","first-page":"592768","DOI":"10.3389\/fphar.2020.592768","volume":"11","author":"X Lin","year":"2020","unstructured":"Lin, X., Xiao, Z., Hu, Y., Zhang, X., & Fan, W. (2020). Combining (18)F-FDG PET\/CT and serum lactate dehydrogenase for prognostic evaluation of small cell Lung Cancer. Frontiers in Pharmacology, 11, 592768. https:\/\/doi.org\/10.3389\/fphar.2020.592768","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10220_CR86","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10555-021-10012-4","volume":"40","author":"I Krencz","year":"2021","unstructured":"Krencz, I., Sztankovics, D., Danko, T., Sebestyen, A., & Khoor, A. (2021). Progression and metastasis of small cell lung carcinoma: The role of the PI3K\/Akt\/mTOR pathway and metabolic alterations. Cancer and Metastasis Reviews, 40(4), 1141\u20131157. https:\/\/doi.org\/10.1007\/s10555-021-10012-4","journal-title":"Cancer and Metastasis Reviews"},{"issue":"4","key":"10220_CR87","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1078-0432.Ccr-13-2270","volume":"20","author":"R Pola\u0144ski","year":"2014","unstructured":"Pola\u0144ski, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., et al. (2014). Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clinical Cancer Research, 20(4), 926\u2013937. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2270","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10220_CR88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/pap.0000000000000219","volume":"26","author":"M Akhtar","year":"2019","unstructured":"Akhtar, M., Haider, A., Rashid, S., & Al-Nabet, A. (2019). Paget\u2019s seed and soil theory of Cancer Metastasis: An idea whose time has come. Advances in Anatomic Pathology, 26(1), 69\u201374. https:\/\/doi.org\/10.1097\/pap.0000000000000219","journal-title":"Advances in Anatomic Pathology"},{"issue":"24","key":"10220_CR89","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/1078-0432.Ccr-16-0460","volume":"22","author":"P Brodt","year":"2016","unstructured":"Brodt, P. (2016). Role of the Microenvironment in Liver Metastasis: From pre- to Prometastatic niches. Clinical Cancer Research, 22(24), 5971\u20135982. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0460","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10220_CR90","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neo.2016.11.005","volume":"19","author":"M Stawowczyk","year":"2017","unstructured":"Stawowczyk, M., Wellenstein, M. D., Lee, S. B., Yomtoubian, S., Durrans, A., Choi, H., et al. (2017). Matrix Metalloproteinase 14 promotes lung cancer by cleavage of heparin-binding EGF-like growth factor. Neoplasia (New York, N.Y.), 19(2), 55\u201364. https:\/\/doi.org\/10.1016\/j.neo.2016.11.005","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"8","key":"10220_CR91","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/0008-5472.Can-16-1978","volume":"77","author":"LE Stevens","year":"2017","unstructured":"Stevens, L. E., Cheung, W. K. C., Adua, S. J., Arnal-Estap\u00e9, A., Zhao, M., Liu, Z., et al. (2017). Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of Micrometastases. Cancer Research, 77(8), 1905\u20131917. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-1978","journal-title":"Cancer Research"},{"key":"10220_CR92","doi-asserted-by":"publisher","unstructured":"Liburkin-Dan, T., Toledano, S., & Neufeld, G. (2022). Lysyl Oxidase Family Enzymes and their role in Tumor Progression. International Journal of Molecular Sciences, 23(11). https:\/\/doi.org\/10.3390\/ijms23116249","DOI":"10.3390\/ijms23116249"},{"issue":"11","key":"10220_CR93","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature Medicine, 19(11), 1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394","journal-title":"Nature Medicine"},{"issue":"1","key":"10220_CR94","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., et al. (2019). The lung microenvironment: An important regulator of tumour growth and metastasis. Nature Reviews Cancer, 19(1), 9\u201331. https:\/\/doi.org\/10.1038\/s41568-018-0081-9","journal-title":"Nature Reviews Cancer"},{"key":"10220_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00108-z","author":"H Wang","year":"2024","unstructured":"Wang, H., Sun, H., Huang, J., Zhang, Z., Cai, G., Wang, C., et al. (2024). Therapeutic targeting ERR\u03b3 suppresses metastasis via extracellular matrix remodeling in small cell lung cancer. Embo Molecular Medicine. https:\/\/doi.org\/10.1038\/s44321-024-00108-z","journal-title":"Embo Molecular Medicine"},{"key":"10220_CR96","doi-asserted-by":"publisher","unstructured":"De Luca, A., Gallo, M., Esposito, C., Morabito, A., & Normanno, N. (2021). Promising role of circulating Tumor cells in the management of SCLC. Cancers (Basel), 13(9). https:\/\/doi.org\/10.3390\/cancers13092029","DOI":"10.3390\/cancers13092029"},{"issue":"4","key":"10220_CR97","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s43018-020-0046-2","volume":"1","author":"KL Simpson","year":"2020","unstructured":"Simpson, K. L., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., et al. (2020). A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. Nat Cancer, 1(4), 437\u2013451. https:\/\/doi.org\/10.1038\/s43018-020-0046-2","journal-title":"Nature Cancer"},{"key":"10220_CR98","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","volume":"1","author":"CA Stewart","year":"2020","unstructured":"Stewart, C. A., Gay, C. M., Xi, Y., Sivajothi, S., Sivakamasundari, V., Fujimoto, J., et al. (2020). Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer, 1, 423\u2013436. https:\/\/doi.org\/10.1038\/s43018-019-0020-z","journal-title":"Nature Cancer"},{"issue":"1","key":"10220_CR99","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1038\/s41598-017-05562-z","volume":"7","author":"L Klameth","year":"2017","unstructured":"Klameth, L., Rath, B., Hochmaier, M., Moser, D., Redl, M., Mungenast, F., et al. (2017). Small cell lung cancer: Model of circulating tumor cell tumorospheres in chemoresistance. Scientific Reports, 7(1), 5337. https:\/\/doi.org\/10.1038\/s41598-017-05562-z","journal-title":"Scientific Reports"},{"issue":"5","key":"10220_CR100","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1200\/jco.2010.33.3716","volume":"30","author":"JM Hou","year":"2012","unstructured":"Hou, J. M., Krebs, M. G., Lancashire, L., Sloane, R., Backen, A., Swain, R. K., et al. (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. Journal of Clinical Oncology, 30(5), 525\u2013532. https:\/\/doi.org\/10.1200\/jco.2010.33.3716","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10220_CR101","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1038\/s41598-021-85743-z","volume":"11","author":"M Maeshiro","year":"2021","unstructured":"Maeshiro, M., Shinriki, S., Liu, R., Nakachi, Y., Komohara, Y., Fujiwara, Y., et al. (2021). Colonization of distant organs by tumor cells generating circulating homotypic clusters adaptive to fluid shear stress. Scientific Reports, 11(1), 6150. https:\/\/doi.org\/10.1038\/s41598-021-85743-z","journal-title":"Scientific Reports"},{"issue":"1","key":"10220_CR102","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trecan.2015.07.009","volume":"1","author":"AC Obenauf","year":"2015","unstructured":"Obenauf, A. C., & Massague, J. (2015). Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer, 1(1), 76\u201391. https:\/\/doi.org\/10.1016\/j.trecan.2015.07.009","journal-title":"Trends Cancer"},{"issue":"2","key":"10220_CR103","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews Cancer, 11(2), 123\u2013134. https:\/\/doi.org\/10.1038\/nrc3004","journal-title":"Nature Reviews Cancer"},{"issue":"7745","key":"10220_CR104","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","volume":"566","author":"BM Szczerba","year":"2019","unstructured":"Szczerba, B. M., Castro-Giner, F., Vetter, M., Krol, I., Gkountela, S., Landin, J., et al. (2019). Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 566(7745), 553\u2013557. https:\/\/doi.org\/10.1038\/s41586-019-0915-y","journal-title":"Nature"},{"issue":"23","key":"10220_CR105","doi-asserted-by":"publisher","first-page":"8613","DOI":"10.1158\/0008-5472.Can-04-2078","volume":"64","author":"JH Im","year":"2004","unstructured":"Im, J. H., Fu, W., Wang, H., Bhatia, S. K., Hammer, D. A., Kowalska, M. A., et al. (2004). Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Research, 64(23), 8613\u20138619. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-2078","journal-title":"Cancer Research"},{"issue":"2","key":"10220_CR106","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/s-2008-1079255","volume":"34","author":"JS Palumbo","year":"2008","unstructured":"Palumbo, J. S. (2008). Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Seminars in Thrombosis and Hemostasis, 34(2), 154\u2013160. https:\/\/doi.org\/10.1055\/s-2008-1079255","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"6","key":"10220_CR107","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/ijc.33247","volume":"148","author":"S Izraely","year":"2021","unstructured":"Izraely, S., & Witz, I. P. (2021). Site-specific metastasis: A cooperation between cancer cells and the metastatic microenvironment. International Journal of Cancer, 148(6), 1308\u20131322. https:\/\/doi.org\/10.1002\/ijc.33247","journal-title":"International Journal of Cancer"},{"issue":"1","key":"10220_CR108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5483\/BMBRep.2016.49.1.239","volume":"49","author":"YH Soung","year":"2016","unstructured":"Soung, Y. H., Nguyen, T., Cao, H., Lee, J., & Chung, J. (2016). Emerging roles of exosomes in cancer invasion and metastasis. Bmb Reports, 49(1), 18\u201325. https:\/\/doi.org\/10.5483\/BMBRep.2016.49.1.239","journal-title":"Bmb Reports"},{"issue":"1","key":"10220_CR109","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12014-021-09339-5","volume":"19","author":"S Pedersen","year":"2022","unstructured":"Pedersen, S., Jensen, K. P., Honor\u00e9, B., Kristensen, S. R., Pedersen, C. H., Szejniuk, W. M., et al. (2022). Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics. Clinical Proteomics, 19(1), 2. https:\/\/doi.org\/10.1186\/s12014-021-09339-5","journal-title":"Clinical Proteomics"},{"issue":"6","key":"10220_CR110","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ncb3169","volume":"17","author":"B Costa-Silva","year":"2015","unstructured":"Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., et al. (2015). Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biology, 17(6), 816\u2013826. https:\/\/doi.org\/10.1038\/ncb3169","journal-title":"Nature Cell Biology"},{"issue":"3","key":"10220_CR111","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10585-012-9540-y","volume":"30","author":"S Sato","year":"2013","unstructured":"Sato, S., Hanibuchi, M., Kuramoto, T., Yamamori, N., Goto, H., Ogawa, H., et al. (2013). Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment. Clinical & Experimental Metastasis, 30(3), 333\u2013344. https:\/\/doi.org\/10.1007\/s10585-012-9540-y","journal-title":"Clinical & Experimental Metastasis"},{"issue":"8","key":"10220_CR112","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc865","volume":"2","author":"AF Chambers","year":"2002","unstructured":"Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563\u2013572. https:\/\/doi.org\/10.1038\/nrc865","journal-title":"Nature Reviews Cancer"},{"issue":"5","key":"10220_CR113","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2353\/ajpath.2007.060886","volume":"170","author":"P Auguste","year":"2007","unstructured":"Auguste, P., Fallavollita, L., Wang, N., Burnier, J., Bikfalvi, A., & Brodt, P. (2007). The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. American Journal of Pathology, 170(5), 1781\u20131792. https:\/\/doi.org\/10.2353\/ajpath.2007.060886","journal-title":"American Journal of Pathology"},{"issue":"6","key":"10220_CR114","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s00125-016-3940-5","volume":"59","author":"JG Jones","year":"2016","unstructured":"Jones, J. G. (2016). Hepatic glucose and lipid metabolism. Diabetologia, 59(6), 1098\u20131103. https:\/\/doi.org\/10.1007\/s00125-016-3940-5","journal-title":"Diabetologia"},{"issue":"1","key":"10220_CR115","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bbcan.2017.04.002","volume":"1868","author":"S Ganapathy-Kanniappan","year":"2017","unstructured":"Ganapathy-Kanniappan, S. (2017). Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities. Biochimica Et Biophysica Acta - Reviews on Cancer, 1868(1), 212\u2013220. https:\/\/doi.org\/10.1016\/j.bbcan.2017.04.002","journal-title":"Biochimica Et Biophysica Acta - Reviews on Cancer"},{"issue":"1","key":"10220_CR116","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","volume":"39","author":"J Feng","year":"2020","unstructured":"Feng, J., Li, J., Wu, L., Yu, Q., Ji, J., Wu, J., et al. (2020). Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research : Cr, 39(1), 126. https:\/\/doi.org\/10.1186\/s13046-020-01629-4","journal-title":"Journal of Experimental & Clinical Cancer Research : Cr"},{"issue":"9","key":"10220_CR117","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41568-021-00383-9","volume":"21","author":"X Li","year":"2021","unstructured":"Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021). The immunological and metabolic landscape in primary and metastatic liver cancer. Nature Reviews Cancer, 21(9), 541\u2013557. https:\/\/doi.org\/10.1038\/s41568-021-00383-9","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"10220_CR118","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2007.10.006","volume":"20","author":"F Winau","year":"2008","unstructured":"Winau, F., Quack, C., Darmoise, A., & Kaufmann, S. H. (2008). Starring stellate cells in liver immunology. Current Opinion in Immunology, 20(1), 68\u201374. https:\/\/doi.org\/10.1016\/j.coi.2007.10.006","journal-title":"Current Opinion in Immunology"},{"issue":"3","key":"10220_CR119","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jhep.2014.04.027","volume":"61","author":"A Carambia","year":"2014","unstructured":"Carambia, A., Freund, B., Schwinge, D., Heine, M., Laschtowitz, A., Huber, S., et al. (2014). TGF-\u03b2-dependent induction of CD4\u207aCD25\u207aFoxp3\u207a tregs by liver sinusoidal endothelial cells. Journal of Hepatology, 61(3), 594\u2013599. https:\/\/doi.org\/10.1016\/j.jhep.2014.04.027","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10220_CR120","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.21965","volume":"47","author":"L Diehl","year":"2008","unstructured":"Diehl, L., Schurich, A., Grochtmann, R., Hegenbarth, S., Chen, L., & Knolle, P. A. (2008). Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8\u2009+\u2009T cell tolerance. Hepatology, 47(1), 296\u2013305. https:\/\/doi.org\/10.1002\/hep.21965","journal-title":"Hepatology"},{"issue":"12","key":"10220_CR121","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/82161","volume":"6","author":"A Limmer","year":"2000","unstructured":"Limmer, A., Ohl, J., Kurts, C., Ljunggren, H. G., Reiss, Y., Groettrup, M., et al. (2000). Efficient presentation of exogenous antigen by liver endothelial cells to CD8\u2009+\u2009T cells results in antigen-specific T-cell tolerance. Nature Medicine, 6(12), 1348\u20131354. https:\/\/doi.org\/10.1038\/82161","journal-title":"Nature Medicine"},{"key":"10220_CR122","doi-asserted-by":"publisher","unstructured":"Baglieri, J., Brenner, D. A., & Kisseleva, T. (2019). The role of Fibrosis and Liver-Associated fibroblasts in the pathogenesis of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 20(7). https:\/\/doi.org\/10.3390\/ijms20071723","DOI":"10.3390\/ijms20071723"},{"issue":"1","key":"10220_CR123","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.immuni.2006.11.011","volume":"26","author":"F Winau","year":"2007","unstructured":"Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P. A., et al. (2007). Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity, 26(1), 117\u2013129. https:\/\/doi.org\/10.1016\/j.immuni.2006.11.011","journal-title":"Immunity"},{"issue":"1","key":"10220_CR124","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/hep.27793","volume":"62","author":"F Heymann","year":"2015","unstructured":"Heymann, F., Peusquens, J., Ludwig-Portugall, I., Kohlhepp, M., Ergen, C., Niemietz, P., et al. (2015). Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology, 62(1), 279\u2013291. https:\/\/doi.org\/10.1002\/hep.27793","journal-title":"Hepatology"},{"issue":"6","key":"10220_CR125","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/s0952-7915(97)80190-2","volume":"9","author":"P Lu","year":"1997","unstructured":"Lu, P., Wang, Y. L., & Linsley, P. S. (1997). Regulation of self-tolerance by CD80\/CD86 interactions. Current Opinion in Immunology, 9(6), 858\u2013862. https:\/\/doi.org\/10.1016\/s0952-7915(97)80190-2","journal-title":"Current Opinion in Immunology"},{"issue":"2","key":"10220_CR126","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/01.shk.0000223130.87382.73","volume":"26","author":"H Yanagida","year":"2006","unstructured":"Yanagida, H., Kaibori, M., Yoshida, H., Habara, K., Yamada, M., Kamiyama, Y., et al. (2006). Hepatic ischemia\/reperfusion upregulates the susceptibility of hepatocytes to confer the induction of inducible nitric oxide synthase gene expression. Shock (Augusta, Ga.), 26(2), 162\u2013168. https:\/\/doi.org\/10.1097\/01.shk.0000223130.87382.73","journal-title":"Shock (Augusta, Ga.)"},{"issue":"1","key":"10220_CR127","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.31644","volume":"74","author":"E Pose","year":"2021","unstructured":"Pose, E., Coll, M., Mart\u00ednez-S\u00e1nchez, C., Zeng, Z., Surewaard, B. G. J., Catal\u00e0, C., et al. (2021). Programmed death Ligand 1 is overexpressed in Liver macrophages in Chronic Liver diseases, and its Blockade improves the antibacterial activity against infections. Hepatology, 74(1), 296\u2013311. https:\/\/doi.org\/10.1002\/hep.31644","journal-title":"Hepatology"},{"issue":"1","key":"10220_CR128","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.esmoop.2020.100003","volume":"6","author":"A Ortega-Franco","year":"2021","unstructured":"Ortega-Franco, A., Ackermann, C., Paz-Ares, L., & Califano, R. (2021). First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: Clinical developments and future directions. ESMO Open, 6(1), 100003. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100003","journal-title":"ESMO Open"},{"issue":"5","key":"10220_CR129","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., et al. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(\u2606). Annals of Oncology, 32(5), 631\u2013641. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.071","journal-title":"Annals of Oncology"},{"issue":"12","key":"10220_CR130","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/jco.20.02212","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko, T. K., Park, K., Govindan, R., Ready, N., Reck, M., Peters, S., et al. (2021). Nivolumab and Ipilimumab as maintenance therapy in extensive-disease small-cell Lung Cancer: CheckMate 451. Journal of Clinical Oncology, 39(12), 1349\u20131359. https:\/\/doi.org\/10.1200\/jco.20.02212","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10220_CR131","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/jco.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Cs\u0151szi, T., et al. (2020). Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line therapy for extensive-stage small-cell Lung Cancer: Randomized, Double-Blind, phase III KEYNOTE-604 study. Journal of Clinical Oncology, 38(21), 2369\u20132379. https:\/\/doi.org\/10.1200\/jco.20.00793","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10220_CR132","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/jco.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu, S. V., Reck, M., Mansfield, A. S., Mok, T., Scherpereel, A., Reinmuth, N., et al. (2021). Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology, 39(6), 619\u2013630. https:\/\/doi.org\/10.1200\/jco.20.01055","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10220_CR133","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., et al. (2021). Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 22(1), 51\u201365. https:\/\/doi.org\/10.1016\/s1470-2045(20)30539-8","journal-title":"The Lancet Oncology"},{"key":"10220_CR134","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jtho.2023.09.027","volume":"18","author":"YF Cheng","year":"2023","unstructured":"Cheng, Y. F., Y. and, Zhao, Y., Huang, D., Li, X., Zhang, P., Kang, M., Yang, N., Zhong, D., Wang, Z., Yu, Y., Zhang, Y., Zhao, J., Qin, T., Chen, C., Leaw, S., Zheng, W., & Song, Y. (2023). OA01.06 First-Line Chemotherapy with or without Tislelizumab for extensive-stage small cell Lung Cancer: RATIONALE-312 phase 3 study. Journal of Thoracic Oncology, 18, S46.","journal-title":"Journal of Thoracic Oncology"},{"key":"10220_CR135","doi-asserted-by":"publisher","unstructured":"Cheng, Y. (2023). LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC). Annals of Oncology, 34, S1334, https:\/\/doi.org\/10.1016\/j.annonc.2023.10.096","DOI":"10.1016\/j.annonc.2023.10.096"},{"issue":"15_suppl","key":"10220_CR136","doi-asserted-by":"publisher","first-page":"9000","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","volume":"38","author":"T Leal","year":"2020","unstructured":"Leal, T., Wang, Y., Dowlati, A., Lewis, D. A., Chen, Y., Mohindra, A. R., et al. (2020). Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Journal of Clinical Oncology, 38(15_suppl), 9000\u20139000. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9000","journal-title":"Journal of Clinical Oncology"},{"key":"10220_CR137","doi-asserted-by":"publisher","unstructured":"Dramatic Improvements in ES-SCLC Survival Seen with Benmelstobart (2023).\u00a0Cancer Discovery, Of1, https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2023-0069","DOI":"10.1158\/2159-8290.Cd-nb2023-0069"},{"issue":"1","key":"10220_CR138","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jtho.2016.09.002","volume":"12","author":"H Yu","year":"2017","unstructured":"Yu, H., Batenchuk, C., Badzio, A., Boyle, T. A., Czapiewski, P., Chan, D. C., et al. (2017). PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 12(1), 110\u2013120. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.002","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"6280","key":"10220_CR139","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N., Furness, A. J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., et al. (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 351(6280), 1463\u20131469. https:\/\/doi.org\/10.1126\/science.aaf1490","journal-title":"Science"},{"issue":"3","key":"10220_CR140","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/JTO.0b013e3182417830","volume":"7","author":"GW Lee","year":"2012","unstructured":"Lee, G. W., Go, S. I., Cho, Y. J., Jeong, Y. Y., Kim, H. C., Lee, D., J., et al. (2012). Hypoxia-inducible factor-1\u03b1 and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: A retrospective study. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 7(3), 528\u2013534. https:\/\/doi.org\/10.1097\/JTO.0b013e3182417830","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"33","key":"10220_CR141","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1200\/jco.2011.35.6923","volume":"29","author":"NE Ready","year":"2011","unstructured":"Ready, N. E., Dudek, A. Z., Pang, H. H., Hodgson, L. D., Graziano, S. L., Green, M. R., et al. (2011). Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. Journal of Clinical Oncology, 29(33), 4436\u20134441. https:\/\/doi.org\/10.1200\/jco.2011.35.6923","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10220_CR142","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/jco.2010.29.3423","volume":"29","author":"DR Spigel","year":"2011","unstructured":"Spigel, D. R., Townley, P. M., Waterhouse, D. M., Fang, L., Adiguzel, I., Huang, J. E., et al. (2011). Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial. Journal of Clinical Oncology, 29(16), 2215\u20132222. https:\/\/doi.org\/10.1200\/jco.2010.29.3423","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10220_CR143","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/jco.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo, M., Boni, L., Ambrosio, F., Camerini, A., Baldini, E., Cinieri, S., et al. (2017). Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide with or without Bevacizumab as First-Line treatment in extensive-disease small-cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology, 35(12), 1281\u20131287. https:\/\/doi.org\/10.1200\/jco.2016.69.4844","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10220_CR144","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10456-019-09698-6","volume":"23","author":"EA Kuczynski","year":"2020","unstructured":"Kuczynski, E. A., & Reynolds, A. R. (2020). Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis, 23(1), 55\u201374. https:\/\/doi.org\/10.1007\/s10456-019-09698-6","journal-title":"Angiogenesis"},{"issue":"8","key":"10220_CR145","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021). Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nature Reviews. Clinical Oncology, 18(8), 527\u2013540. https:\/\/doi.org\/10.1038\/s41571-021-00496-y","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"10220_CR146","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","volume":"16","author":"Y Fan","year":"2021","unstructured":"Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., et al. (2021). Camrelizumab Plus Apatinib in extensive-stage SCLC (PASSION): A Multicenter, Two-Stage, phase 2 trial. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(2), 299\u2013309. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.002","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"8","key":"10220_CR147","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41416-019-0583-6","volume":"121","author":"Y Xu","year":"2019","unstructured":"Xu, Y., Huang, Z., Lu, H., Yu, X., Li, Y., Li, W., et al. (2019). Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: A phase II, single-arm, multicentre, prospective study. British Journal of Cancer, 121(8), 640\u2013646. https:\/\/doi.org\/10.1038\/s41416-019-0583-6","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10220_CR148","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/bjc.2017.465","volume":"118","author":"JM Sun","year":"2018","unstructured":"Sun, J. M., Lee, K. H., Kim, B. S., Kim, H. G., Min, Y. J., Yi, S. Y., et al. (2018). Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: A multicentre, randomised, placebo-controlled phase II study (KCSG-LU12-07). British Journal of Cancer, 118(5), 648\u2013653. https:\/\/doi.org\/10.1038\/bjc.2017.465","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10220_CR149","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/bjc.2017.137","volume":"117","author":"F Koinis","year":"2017","unstructured":"Koinis, F., Agelaki, S., Karavassilis, V., Kentepozidis, N., Samantas, E., Peroukidis, S., et al. (2017). Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: A multicentre phase II study of the Hellenic Oncology Research Group. British Journal of Cancer, 117(1), 8\u201314. https:\/\/doi.org\/10.1038\/bjc.2017.137","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10220_CR150","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s11684-021-0916-8","volume":"16","author":"J Shi","year":"2022","unstructured":"Shi, J., Cheng, Y., Wang, Q., Li, K., Wu, L., Han, B., et al. (2022). Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: Subgroup analysis of a randomized phase 2 study (ALTER1202). Frontiers in Medicine, 16(5), 766\u2013772. https:\/\/doi.org\/10.1007\/s11684-021-0916-8","journal-title":"Frontiers in Medicine"},{"key":"10220_CR151","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.lungcan.2022.09.003","volume":"173","author":"W Zhang","year":"2022","unstructured":"Zhang, W., Deng, P., Kong, T., Zhang, B., Qian, F., Dong, Y., et al. (2022). Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A multi-center, prospective study (ACTION-2). Lung Cancer, 173, 43\u201348. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.003","journal-title":"Lung Cancer"},{"key":"10220_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03132-1","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y., Chen, J., Zhang, W., Xie, C., Hu, Q., Zhou, N., et al. (2024). Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial. Nature Medicine. https:\/\/doi.org\/10.1038\/s41591-024-03132-1","journal-title":"Nature Medicine"},{"issue":"4","key":"10220_CR153","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/cam4.4507","volume":"11","author":"Y Cheng","year":"2022","unstructured":"Cheng, Y., Wang, Q., Li, K., Shi, J., Wu, L., Han, B., et al. (2022). Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. Cancer Medicine, 11(4), 1081\u20131087. https:\/\/doi.org\/10.1002\/cam4.4507","journal-title":"Cancer Medicine"},{"key":"10220_CR154","doi-asserted-by":"publisher","unstructured":"Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020). Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment.\u00a0Frontiers in Immunology, 11, 1956, https:\/\/doi.org\/10.3389\/fimmu.2020.01956","DOI":"10.3389\/fimmu.2020.01956"},{"issue":"15","key":"10220_CR155","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1158\/0008-5472.Can-17-2176","volume":"78","author":"L Meder","year":"2018","unstructured":"Meder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., et al. (2018). Combined VEGF and PD-L1 blockade Displays Synergistic Treatment effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Research, 78(15), 4270\u20134281. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-2176","journal-title":"Cancer Research"},{"issue":"2","key":"10220_CR156","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00432-021-03858-2","volume":"148","author":"Q Chen","year":"2022","unstructured":"Chen, Q., Li, Y., Zhang, W., Wang, C., Yang, S., & Guo, Q. (2022). Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: A retrospective study. Journal of Cancer Research and Clinical Oncology, 148(2), 401\u2013408. https:\/\/doi.org\/10.1007\/s00432-021-03858-2","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10220_CR157","doi-asserted-by":"publisher","first-page":"e390794","DOI":"10.1200\/edbk_390794","volume":"43","author":"L Fernandez-Cuesta","year":"2023","unstructured":"Fernandez-Cuesta, L., Sexton-Oates, A., Bayat, L., Foll, M., Lau, S. C. M., & Leal, T. (2023). Spotlight on small-cell lung cancer and other lung neuroendocrine neoplasms. American Society of Clinical Oncology\u00a0Educational Book, 43, e390794. https:\/\/doi.org\/10.1200\/edbk_390794","journal-title":"American Society of Clinical Oncology\u00a0Educational Book"},{"issue":"2","key":"10220_CR158","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","volume":"15","author":"TK Owonikoko","year":"2020","unstructured":"Owonikoko, T. K., Niu, H., Nackaerts, K., Csoszi, T., Ostoros, G., Mark, Z., et al. (2020). Randomized Phase II study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line therapy for SCLC: Primary and correlative biomarker analyses. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 15(2), 274\u2013287. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.013","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"9","key":"10220_CR159","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall, F., Jao, K., Greillier, L., Cho, B. C., Penkov, K., Reguart, N., et al. (2021). Efficacy and safety of Rovalpituzumab Tesirine compared with Topotecan as second-line therapy in DLL3-High SCLC: Results from the phase 3 TAHOE Study. Journal of Thoracic Oncology\u202f: Official Publication of the International Association for the Study of Lung Cancer, 16(9), 1547\u20131558. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.009","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"9","key":"10220_CR160","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","volume":"16","author":"ML Johnson","year":"2021","unstructured":"Johnson, M. L., Zvirbule, Z., Laktionov, K., Helland, A., Cho, B. C., Gutierrez, V., et al. (2021). Rovalpituzumab Tesirine as a maintenance Therapy after First-Line platinum-based chemotherapy in patients with extensive-Stage-SCLC: Results from the phase 3 MERU Study. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(9), 1570\u20131581. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.012","journal-title":"Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"16_suppl","key":"10220_CR161","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.1200\/JCO.2023.41.16_suppl.8502","volume":"41","author":"E Felip","year":"2023","unstructured":"Felip, E., Kuboki, Y., Morgensztern, D., Sayehli, C., Sanmamed, M. F., Arriola, E., et al. (2023). First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)\/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). Journal of Clinical Oncology, 41(16_suppl), 8502\u20138502. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8502","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10220_CR162","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/jco.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares, L., Champiat, S., Lai, W. V., Izumi, H., Govindan, R., Boyer, M., et al. (2023). Tarlatamab, a first-in-class DLL3-Targeted bispecific T-Cell engager, in recurrent small-cell lung Cancer: An Open-Label, phase I study. Journal of Clinical Oncology, 41(16), 2893\u20132903. https:\/\/doi.org\/10.1200\/jco.22.02823","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10220_CR163","doi-asserted-by":"publisher","first-page":"8566","DOI":"10.1200\/JCO.2022.40.16_suppl.8566","volume":"40","author":"ML Johnson","year":"2022","unstructured":"Johnson, M. L., Dy, G. K., Mamdani, H., Dowlati, A., Schoenfeld, A. J., Pacheco, J. M., et al. (2022). Interim results of an ongoing phase 1\/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. Journal of Clinical Oncology, 40(16_suppl), 8566\u20138566. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8566","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10220_CR164","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1200\/JCO.2024.42.16_suppl.8090","volume":"42","author":"H Beltran","year":"2024","unstructured":"Beltran, H., Johnson, M. L., Jain, P., Schenk, E. L., Sanborn, R. E., Thompson, J. R., et al. (2024). Updated results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). Journal of Clinical Oncology, 42(16_suppl), 8090\u20138090. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8090","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10220_CR165","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","volume":"42","author":"SR Chandana","year":"2024","unstructured":"Chandana, S. R., Choudhury, N. J., Dowlati, A., Chiang, A. C., Garmezy, B., Kim, J. H., et al. (2024). First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 42(16_suppl), 3001\u20133001. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3001","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10220_CR166","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1200\/JCO.2023.41.16_suppl.3017","volume":"41","author":"J Wang","year":"2023","unstructured":"Wang, J., Duan, J., Xing, L., Sun, Y., Guo, W., Wang, H., et al. (2023). ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced solid tumor. Journal of Clinical Oncology, 41(16_suppl), 3017\u20133017. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3017","journal-title":"Journal of Clinical Oncology"},{"key":"10220_CR167","doi-asserted-by":"publisher","unstructured":"Annals of Oncology. (2022). 33 (suppl_7): S197-S224. https:\/\/doi.org\/10.1016\/annonc\/annonc1049","DOI":"10.1016\/annonc\/annonc1049"},{"issue":"16_suppl","key":"10220_CR168","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1200\/JCO.2024.42.16_suppl.8093","volume":"42","author":"J Wang","year":"2024","unstructured":"Wang, J., Duan, J., Sun, Y., Xing, L., Han, L., Wang, Q., et al. (2024). ARTEMIS-001: Data from a phase 1a\/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). Journal of Clinical Oncology, 42(16_suppl), 8093\u20138093. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8093","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10220_CR169","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2023.41.16_suppl.8504","volume":"41","author":"J Miao","year":"2023","unstructured":"Miao, J., Reckamp, K. L., Gay, C. M., Byers, L. A., Zhao, Y., Redman, M. W., et al. (2023). SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab\u2009+\u2009talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology, 41(16_suppl), 8504\u20138504. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8504","journal-title":"Journal of Clinical Oncology"},{"issue":"7_Supplement","key":"10220_CR170","doi-asserted-by":"publisher","first-page":"6206","DOI":"10.1158\/1538-7445.Am2023-6206","volume":"83","author":"K Ramkumar","year":"2023","unstructured":"Ramkumar, K., Stewart, C. A., Tanimoto, A., Wang, Q., Xi, Y., Morris, B. B., et al. (2023). Abstract 6206: Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer. Cancer Research, 83(7_Supplement), 6206\u20136206. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-6206","journal-title":"Cancer Research"},{"issue":"2","key":"10220_CR171","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/1535-7163.Mct-22-0365","volume":"22","author":"G Wildey","year":"2023","unstructured":"Wildey, G., Shay, A. M., McColl, K. S., Yoon, S., Shatat, M. A., Perwez, A., et al. (2023). Retinoblastoma expression and targeting by CDK4\/6 inhibitors in small cell Lung Cancer. Molecular Cancer Therapeutics, 22(2), 264\u2013273. https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0365","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10220_CR172","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","volume":"72","author":"V Ratziu","year":"2020","unstructured":"Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., et al. (2020). Cenicriviroc Treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR Study. Hepatology, 72(3), 892\u2013905. https:\/\/doi.org\/10.1002\/hep.31108","journal-title":"Hepatology"},{"issue":"1","key":"10220_CR173","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/0008-5472.Can-15-0869","volume":"76","author":"E Van Overmeire","year":"2016","unstructured":"Van Overmeire, E., Stijlemans, B., Heymann, F., Keirsse, J., Morias, Y., Elkrim, Y., et al. (2016). M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the Tumor Microenvironment. Cancer Research, 76(1), 35\u201342. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-0869","journal-title":"Cancer Research"},{"key":"10220_CR174","doi-asserted-by":"publisher","unstructured":"Bhattacharjee, S., Hamberger, F., Ravichandra, A., Miller, M., Nair, A., Affo, S., et al. (2021). Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. Journal of Clinical Investigation, 131(11). https:\/\/doi.org\/10.1172\/jci146987","DOI":"10.1172\/jci146987"},{"issue":"1","key":"10220_CR175","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/ol.2019.11092","volume":"19","author":"X Shang","year":"2020","unstructured":"Shang, X., Lin, J., Li, Z., & Wang, H. (2020). Radiotherapy may improve survival of ES\u2013SCLC with distant metastasis only for patients with one metastatic site: A population\u2013based study. Oncol Lett, 19(1), 139\u2013146. https:\/\/doi.org\/10.3892\/ol.2019.11092","journal-title":"Oncology Letters"},{"issue":"3","key":"10220_CR176","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jncc.2022.06.004","volume":"2","author":"K Alrabiah","year":"2022","unstructured":"Alrabiah, K., Liao, G., Shen, Q., Chiang, C. L., & Dawson, L. A. (2022). The evolving role of radiation therapy as treatment for liver metastases. Journal of the National Cancer Center, 2(3), 183\u2013187. https:\/\/doi.org\/10.1016\/j.jncc.2022.06.004","journal-title":"Journal of the National Cancer Center"},{"issue":"1","key":"10220_CR177","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","volume":"13","author":"A Mahadevan","year":"2018","unstructured":"Mahadevan, A., Blanck, O., Lanciano, R., Peddada, A., Sundararaman, S., D\u2019Ambrosio, D., et al. (2018). Stereotactic body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch\u00ae Patient Registry. Radiation Oncology, 13(1), 26. https:\/\/doi.org\/10.1186\/s13014-018-0969-2","journal-title":"Radiation Oncology"},{"issue":"6","key":"10220_CR178","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria, S., Coleman, C. N., & Formenti, S. C. (2016). Radiotherapy: Changing the game in Immunotherapy. Trends Cancer, 2(6), 286\u2013294. https:\/\/doi.org\/10.1016\/j.trecan.2016.05.002","journal-title":"Trends Cancer"},{"key":"10220_CR179","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Xie, Y., Gong, Y., Huang, M., Li, J., Zhang, L., et al. (2024). 194MO phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide\/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results. ESMO Open, 9. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102767","DOI":"10.1016\/j.esmoop.2024.102767"},{"issue":"10","key":"10220_CR180","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.1634\/theoncologist.2018-0337","volume":"24","author":"F Izzo","year":"2019","unstructured":"Izzo, F., Granata, V., Grassi, R., Fusco, R., Palaia, R., Delrio, P., et al. (2019). Radiofrequency ablation and microwave ablation in liver tumors: An update. The Oncologist, 24(10), e990\u2013e1005. https:\/\/doi.org\/10.1634\/theoncologist.2018-0337","journal-title":"The Oncologist"},{"key":"10220_CR181","doi-asserted-by":"publisher","first-page":"877273","DOI":"10.3389\/fonc.2022.877273","volume":"12","author":"ZY Zhang","year":"2022","unstructured":"Zhang, Z. Y., Jiang, A. N., Yang, W., Yan, K., Wu, W., Wang, S., et al. (2022). Percutaneous Radiofrequency ablation is an effective method for local control of Liver metastases from Lung Cancer. Frontiers in Oncology, 12, 877273. https:\/\/doi.org\/10.3389\/fonc.2022.877273","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"10220_CR182","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11154-017-9431-2","volume":"18","author":"L de Mestier","year":"2017","unstructured":"de Mestier, L., Zappa, M., Hentic, O., Vilgrain, V., & Ruszniewski, P. (2017). Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord, 18(4), 459\u2013471. https:\/\/doi.org\/10.1007\/s11154-017-9431-2","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"10220_CR183","doi-asserted-by":"publisher","unstructured":"Ramdhani, K., & Braat, A. (2022). The evolving role of Radioembolization in the treatment of neuroendocrine liver metastases. Cancers (Basel), 14(14). https:\/\/doi.org\/10.3390\/cancers14143415","DOI":"10.3390\/cancers14143415"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10220-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10220-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10220-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T22:56:19Z","timestamp":1743288979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10220-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":183,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10220"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10220-8","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}